Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.

Male Humans Gallium Radioisotopes Gallium Isotopes Positron Emission Tomography Computed Tomography / methods Prostatectomy Neoplasm Recurrence, Local / diagnostic imaging Prostatic Neoplasms / diagnostic imaging

Outcome prediction PSMA-PET/CT Personalization Prostate cancer Radiomics Salvage radiotherapy

Journal

European journal of nuclear medicine and molecular imaging

ISSN: 1619-7089

Titre abrégé: Eur J Nucl Med Mol Imaging

Pays: Germany

ID NLM: 101140988

Informations de publication

Date de publication:
Jul 2023

Historique:

received: 01 12 2022

accepted: 07 03 2023

medline: 12 6 2023

pubmed: 18 3 2023

entrez: 17 3 2023

Statut: ppublish

Résumé

To develop a CT-based radiomic signature to predict biochemical recurrence (BCR) in prostate cancer patients after sRT guided by positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET). Consecutive patients, who underwent Among 99 patients, median interval until BCR was the radiomic models outperformed clinical models and combined clinical-radiomic models for prediction of BCR with a C-index of 0.71 compared to 0.53 and 0.63 in the test sets, respectively. In contrast to the other models, the radiomic model achieved significantly improved patient stratification in Kaplan-Meier analysis. The radiomic and clinical-radiomic model achieved a significantly better time-dependent net reclassification improvement index (0.392 and 0.762, respectively) compared to the clinical model. Decision curve analysis demonstrated a clinical net benefit for both models. Mean intensity was the most predictive radiomic feature. This is the first study to develop a PSMA-PET-guided CT-based radiomic model to predict BCR after sRT. The radiomic models outperformed clinical models and might contribute to guide personalized treatment decisions.

Identifiants

DOI: 10.1007/s00259-023-06195-3 PMID: 36929180 PMC: PMC10250433

pubmed: 36929180

doi: 10.1007/s00259-023-06195-3

pii: 10.1007/s00259-023-06195-3

pmc: PMC10250433

doi:

Substances chimiques

Gallium Radioisotopes 0

Gallium Isotopes 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2537-2547

Subventions

Organisme : Deutschen Konsortium für Translationale Krebsforschung

ID : IMPRO-REC

Informations de copyright

Références

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.

doi: 10.1016/j.eururo.2014.03.011 pubmed: 24680359

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325–32.

doi: 10.1001/jama.291.11.1325 pubmed: 15026399

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263–82.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–54.

doi: 10.1200/JCO.2016.67.9647 pubmed: 27528718

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.

doi: 10.1001/jamaoncol.2019.0096 pubmed: 30920593 pmcid: 6567829

Schmidt-Hegemann NS, Eze C, Li M, Rogowski P, Schaefer C, Stief C, et al. Impact of (68)Ga-PSMA PET/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis. J Nucl Med. 2019;60(7):963–70.

doi: 10.2967/jnumed.118.220855 pubmed: 30552203 pmcid: 6604695

Peeken JC, Asadpour R, Specht K, Chen EY, Klymenko O, Akinkuoroye V, et al. MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiother Oncol. 2021;164:73–82.

doi: 10.1016/j.radonc.2021.08.023 pubmed: 34506832

Peeken JC, Neumann J, Asadpour R, Leonhardt Y, Moreira JR, Hippe DS, et al. Prognostic assessment in high-grade soft-tissue sarcoma patients: a comparison of semantic image analysis and radiomics. Cancers. 2021;13(8):1929.

doi: 10.3390/cancers13081929 pubmed: 33923697 pmcid: 8073388

Peeken JC, Wiestler B, Combs SE. Image-guided radiooncology: the potential of radiomics in clinical application. In: Schober O, Kiessling F, Debus J, editors. Molecular imaging in oncology. Cham: Springer International Publishing; 2020. p. 773–94.

doi: 10.1007/978-3-030-42618-7_24

Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9(9):2595–605.

doi: 10.7150/thno.32376 pubmed: 31131055 pmcid: 6525993

Spohn SKB, Bettermann AS, Bamberg F, Benndorf M, Mix M, Nicolay NH, et al. Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics. 2021;11(16):8027–42.

doi: 10.7150/thno.61207 pubmed: 34335978 pmcid: 8315055

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.

Spohn SKB, Farolfi A, Schandeler S, Vogel MME, Ruf J, Mix M, et al. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis. Eur J Nucl Med Mol Imaging. 2022;50(1):218–27.

Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626–38.

Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, et al. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol. 2019;141:208–13.

doi: 10.1016/j.radonc.2019.07.002 pubmed: 31431386

van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Can Res. 2017;77(21):e104–7.

doi: 10.1158/0008-5472.CAN-17-0339

Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges J-P, et al. Intratumor heterogeneity characterized by textural features on baseline <sup>18</sup>F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–78.

doi: 10.2967/jnumed.110.082404 pubmed: 21321270

Zwanenburg A, Vallières M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.

doi: 10.1148/radiol.2020191145 pubmed: 32154773

RabascoMeneghetti A, Zwanenburg A, Leger S, Leger K, Troost EGC, Linge A, et al. Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clin Transl Radiat Oncol. 2021;26:62–70.

doi: 10.1016/j.ctro.2020.11.011

Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.

doi: 10.1111/j.0006-341X.2000.00337.x pubmed: 10877287

Zwanenburg A. familiar: Vignettes and Documentation. 2021.

Liu M, Kapadia AS, Etzel CJ. Evaluating a new risk marker’s predictive contribution in survival models. J Stat Theory Pract. 2010;4(4):845–55.

doi: 10.1080/15598608.2010.10412022 pubmed: 22984361 pmcid: 3439820

Sjoberg DD. dcurves: decision curve analysis for model evaluation. 2022.

Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011;12(3):203–14.

doi: 10.1093/bib/bbr001 pubmed: 21324971 pmcid: 3105299

Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74.

doi: 10.1177/0272989X06295361 pubmed: 17099194 pmcid: 2577036

Bourbonne V, Fournier G, Vallières M, Lucia F, Doucet L, Tissot V, et al. External validation of an MRI-derived radiomics model to predict biochemical recurrence after surgery for high-risk prostate cancer. Cancers (Basel). 2020;12(4).

Shiradkar R, Ghose S, Jambor I, Taimen P, Ettala O, Purysko AS, et al. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: preliminary findings. J Magn Reson Imaging. 2018;48(6):1626–36.

doi: 10.1002/jmri.26178 pubmed: 29734484 pmcid: 6222024

Zhong QZ, Long LH, Liu A, Li CM, Xiu X, Hou XY, et al. Radiomics of multiparametric MRI to predict biochemical recurrence of localized prostate cancer after radiation therapy. Front Oncol. 2020;10:731.

doi: 10.3389/fonc.2020.00731 pubmed: 32477949 pmcid: 7235325

Osman SOS, Leijenaar RTH, Cole AJ, Lyons CA, Hounsell AR, Prise KM, et al. Computed tomography-based radiomics for risk stratification in prostate cancer. Int J Radiat Oncol Biol Phys. 2019;105(2):448–56.

doi: 10.1016/j.ijrobp.2019.06.2504 pubmed: 31254658

Bosetti DG, Ruinelli L, Piliero MA, van der Gaag LC, Pesce GA, Valli M, et al. Cone-beam computed tomography-based radiomics in prostate cancer: a mono-institutional study. Strahlenther Onkol. 2020;196(10):943–51.

doi: 10.1007/s00066-020-01677-x pubmed: 32875372

Tanadini-Lang S, Bogowicz M, Veit-Haibach P, Huellner M, Pauli C, Shukla V, et al. Exploratory radiomics in computed tomography perfusion of prostate cancer. Anticancer Res. 2018;38(2):685–90.

pubmed: 29374691

Peeken JC, Shouman MA, Kroenke M, Rauscher I, Maurer T, Gschwend JE, et al. A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. Eur J Nucl Med Mol Imaging. 2020;47(13):2968–77.

doi: 10.1007/s00259-020-04864-1 pubmed: 32468251 pmcid: 7680305

Acar E, Leblebici A, Ellidokuz BE, Başbınar Y, Kaya G. Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. Br J Radiol. 2019;92(1101):20190286.

doi: 10.1259/bjr.20190286 pubmed: 31219712 pmcid: 6732932

Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, et al. Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy. Int J Radiat Oncol Biol Phys. 2022;113(5):1015–24.

doi: 10.1016/j.ijrobp.2022.04.048 pubmed: 35659629